These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25554577)

  • 1. Workshop on measuring estrogen exposure and metabolism: Summary of the presentations.
    Santen RJ; Demers LM; Ziegler RG
    Steroids; 2015 Jul; 99(Pt A):1-7. PubMed ID: 25554577
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Lønning PE; Haynes BP; Dowsett M
    Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-high sensitivity analysis of estrogens for special populations in serum and plasma by liquid chromatography-mass spectrometry: Assay considerations and suggested practices.
    Wang Q; Mesaros C; Blair IA
    J Steroid Biochem Mol Biol; 2016 Sep; 162():70-9. PubMed ID: 26767303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent evidence about aromatase in the breast carcinoma].
    Suzuki T; Moriya T; Sasano H
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():106-10. PubMed ID: 17682147
    [No Abstract]   [Full Text] [Related]  

  • 5. Steroid metabolism in breast cancer.
    Foster PA
    Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
    Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
    Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry: application to steroid and peptide research.
    Shackleton CH
    Endocr Rev; 1985; 6(3):441-86. PubMed ID: 3896770
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
    Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
    Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
    Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
    Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fate and levels of steroid oestrogens and androgens in waste stabilisation ponds: quantification by liquid chromatography-tandem mass spectrometry.
    Coleman HM; Le-Minh N; Khan SJ; Short MD; Chernicharo C; Stuetz RM
    Water Sci Technol; 2010; 61(3):677-84. PubMed ID: 20150704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors: rationale and use in breast cancer.
    Osborne C; Tripathy D
    Annu Rev Med; 2005; 56():103-16. PubMed ID: 15660504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
    Santen RJ; Demers L; Ohorodnik S; Settlage J; Langecker P; Blanchett D; Goss PE; Wang S
    Steroids; 2007 Jul; 72(8):666-71. PubMed ID: 17588628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone metabolisms of aromatase-knockout mice in male].
    Inada M; Miyaura C
    Clin Calcium; 2006 Mar; 16(3):469-73. PubMed ID: 16508130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women.
    Lawrence JA; Malpas PB; Sigman CC; Kelloff GJ
    J Cell Biochem Suppl; 2000; 34():103-14. PubMed ID: 10762022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
    Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
    de Jong PC; van de Ven J; Nortier HW; Maitimu-Smeele I; Donker TH; Thijssen JH; Slee PH; Blankenstein RA
    Cancer Res; 1997 Jun; 57(11):2109-11. PubMed ID: 9187104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen metabolites and breast cancer.
    Santen RJ; Yue W; Wang JP
    Steroids; 2015 Jul; 99(Pt A):61-6. PubMed ID: 25168343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracrinology of estrogens and androgens in breast carcinoma.
    Sasano H; Suzuki T; Miki Y; Moriya T
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):181-5. PubMed ID: 17933521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
    Kendall A; Dowsett M
    Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.